Loading clinical trials...
Loading clinical trials...
A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection
Conditions
Interventions
IMI/REL
Active Control
+1 more
Locations
67
United States
Banner University Medical Center ( Site 0356)
Tucson, Arizona, United States
Miller Children's & Women's Hospital ( Site 0349)
Long Beach, California, United States
Rady Children's Hospital-San Diego ( Site 0347)
San Diego, California, United States
Tufts Medical Center-Floating Hospital for Children ( Site 0350)
Boston, Massachusetts, United States
University of New Mexico ( Site 0358)
Albuquerque, New Mexico, United States
University Hospital ( Site 0360)
San Antonio, Texas, United States
Start Date
October 8, 2019
Primary Completion Date
May 7, 2024
Completion Date
May 7, 2024
Last Updated
February 5, 2026
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions